Stock IKNA IKENA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.33 USD +2.31% Intraday chart for Ikena Oncology, Inc. +2.31% -32.49%
Mar. 12 Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 12 North American Morning Briefing : Inflation Data -2- DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ikena Oncology : Corporate Presentation - April 2024
PU
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
GL
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
AQ
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Inflation Data -2-
DJ
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
GL
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
GL
Ikena Oncology, Inc. Announces Executive Changes
CI
Ikena Oncology to Cut 35% of Workforce to Extend Cash Runway Into H2 2026
MT
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
GL
Ikena Oncology, Inc. Provides Corporate Updates
CI
Top Premarket Decliners
MT
HC Wainwright Adjusts Ikena Oncology Price Target to $11 From $18, Maintains Buy Rating
MT
Wedbush Lowers Ikena Oncology's Price Target to $8 From $11, Moves Estimates Launch Timings for IK-930; Maintains Outperform Rating
MT
Ikena Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
GL
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
AQ
Ikena Oncology, Inc. Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial
CI
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKNA Stock
  4. News Ikena Oncology, Inc.